Madhu Chaudhry
Distinguished in Breast Cancer

Dr. Madhu Chaudhry

Oncology | Hematology
Duke Health
Maria Parh Cancer Center (Duke Cancer Network)
566 Ruin Creek Rd, 
Henderson, NC 
On Staff At
Accepting New Patients
Offers Telehealth

Distinguished in Breast Cancer
Duke Health
Maria Parh Cancer Center (Duke Cancer Network)
566 Ruin Creek Rd, 
Henderson, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

My primary focus is to deliver high-quality and compassionate care to patients. I aim to treat all my patients like I would want my own family members to be treated. My grandmother died of gall bladder cancer. I accompanied her to all her appointments and that experience led me to choose the field of hematology-oncology. Trust between patients and their oncologists is paramount, and I strive to be my patients' trusted friend. Open discussion of all available treatment options and active participation of the patient is extremely important to me. Making patients aware of all evidence-based treatments and ongoing clinical trials before we create a mutually agreed upon treatment plan is crucial. I am always available to discuss various issues that may arise as part of a patient's treatment plan.

Dr. Chaudhry is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Relapsed Refractory Multiple Myeloma (RRMM), and Multiple Myeloma.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 11 clinical trials in the study of Breast Cancer.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NC
Board Certifications
American Board Of Internal Med, Internal Medicine
American Board Of Internal Med, Medical Oncology
American Board Of Internal Med, Hematology
Fellowships
Hematology and Oncology, University of Maryland
Hospital Affiliations
Scotland Memorial Hospital
Southeastern Regional Medical Center
Languages Spoken
English
Hindi
Punjabi
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Maria Parh Cancer Center (Duke Cancer Network)
566 Ruin Creek Rd, Henderson, NC 27536
Call: 252-436-1148
Other Locations
Scotland Cancer Treatment Center (Duke Cancer Network)
500 Lauchwood Dr, Laurinburg, NC 28352
Call: 910-291-7630

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


11 Clinical Trials

BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 2
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 10 Less Clinical Trials

1 Total Publications

The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial.
The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 20, 2019
Similar Doctors
Katherine E. Reeder-Hayes
Elite in Breast Cancer
Dr. Katherine E. Reeder-Hayes
Hematology | Oncology
Elite in Breast Cancer
Dr. Katherine E. Reeder-Hayes
Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (44.9 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Katherine Reeder-Hayes is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Reeder-Hayes is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Reeder-Hayes is currently accepting new patients.

Carey K. Anders
Elite in Breast Cancer
Dr. Carey K. Anders
Oncology
Elite in Breast Cancer
Dr. Carey K. Anders
Oncology

Duke Cancer Center Brain Tumor Clinic

20 Duke Medicine Cir, 
Durham, NC 
 (35.4 miles away)
919-684-5301
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

My clinical practice if focused on the care of patients with breast cancer, particularly those diagnosed at a younger age and those with recurrence in the central nervous system. I am committed to the care of patients with breast cancer brain metastases, and I am honored to serve as the Medical Director of the Brain and Spine Metastases Program in the Duke Cancer Center. In this role, our multidisciplinary team provides well-coordinated care for patients with breast cancer and other solid tumor types that have metastasized to the central nervous system. In addition, I enjoy helping young women diagnosed with breast cancer navigate their treatment decisions to ensure both excellent medical care and attention to individual challenges, such as future fertility, sequelae of treatment on longer-term health, and impact on current and future relationships. When not working, I enjoy running, reading, and traveling with my family. Dr. Anders is rated as an Elite provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Brain Tumor, Triple-Negative Breast Cancer, and Metastatic Brain Tumor.

Hyman B. Muss
Elite in Breast Cancer
Dr. Hyman B. Muss
Hematology Oncology | Hematology | Oncology
Elite in Breast Cancer
Dr. Hyman B. Muss
Hematology Oncology | Hematology | Oncology
143 W Franklin St, 
Chapel Hill, NC 
 (44.8 miles away)
919-966-4131
Languages Spoken:
English
See accepted insurances

Hyman Muss is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Muss is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

VIEW MORE BREAST CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chaudhry's expertise for a condition
ConditionClose
    • Distinguished
    • Breast Cancer
      Dr. Chaudhry is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Paget Disease of the Breast
      Dr. Chaudhry is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Advanced
    • Adult Immune Thrombocytopenia
      Dr. Chaudhry is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Angiosarcoma
      Dr. Chaudhry is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Chronic B-Cell Leukemia (CBCL)
      Dr. Chaudhry is
      Advanced
      . Learn about Chronic B-Cell Leukemia (CBCL).
      See more Chronic B-Cell Leukemia (CBCL) experts
    • Chronic Lymphocytic Leukemia (CLL)
      Dr. Chaudhry is
      Advanced
      . Learn about Chronic Lymphocytic Leukemia (CLL).
      See more Chronic Lymphocytic Leukemia (CLL) experts
    • Gastric Lymphoma
      Dr. Chaudhry is
      Advanced
      . Learn about Gastric Lymphoma.
      See more Gastric Lymphoma experts
    • Hemangioma Thrombocytopenia Syndrome
      Dr. Chaudhry is
      Advanced
      . Learn about Hemangioma Thrombocytopenia Syndrome.
      See more Hemangioma Thrombocytopenia Syndrome experts
    View All 15 Advanced Conditions
    • Experienced
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Chaudhry is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anal Cancer
      Dr. Chaudhry is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Anemia
      Dr. Chaudhry is
      Experienced
      . Learn about Anemia.
      See more Anemia experts
    • Aplastic Anemia
      Dr. Chaudhry is
      Experienced
      . Learn about Aplastic Anemia.
      See more Aplastic Anemia experts
    • Atypical Hemolytic Uremic Syndrome (aHUS)
      Dr. Chaudhry is
      Experienced
      . Learn about Atypical Hemolytic Uremic Syndrome (aHUS).
      See more Atypical Hemolytic Uremic Syndrome (aHUS) experts
    • B-Cell Lymphoma
      Dr. Chaudhry is
      Experienced
      . Learn about B-Cell Lymphoma.
      See more B-Cell Lymphoma experts
    View All 59 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.